This week’s bulletin is later than usual as we’re attending Horizons’ 14th annual conference in New York City. But, there’s plenty to cover: MAPS’ new funding stream, atai’s increased stake in COMPASS Pathways, a study on the interaction between an SSRI and psilocybin, and more… At the close of Thursday’s Business Forum here at Horizons, Vine Ventures’ Ryan Zurrer announced The Regenerative…


Previous articleCOMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
Next articlePT276 – Micah Haskell-Hoehl – Healing, Equity, and Federal Policy